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A systematic review on the role of 
bivalirudin in patients undergoing 
percutaneous coronary interventions: 
primus inter pares or a falling star?
ABSTRACT
Intracoronary thrombosis triggered by ruptured or eroded atherosclerotic plaques constitutes the predom-
inant underlying cause of acute coronary syndromes (ACS). Thrombin is considered a central enzyme 
in hemostasis and thrombosis, and a well-established target for anticoagulant therapies. Bivalirudin was 
introduced in the clinical practice as a promising, reversible, direct thrombin inhibitor with a predictable 
anticoagulant effect. Initial randomized clinical trials demonstrated that bivalirudin compared with heparin 
on top of a glycoprotein IIb/IIIa inhibitor was associated with a significant reduction of major bleeding 
and favorable net clinical outcomes in patients undergoing percutaneous coronary interventions (PCI). 
The HORIZON-AMI trial even indicated mortality benefit in bivalirudin-treated patients. Thereby, the 2011 and 
2012 European Society of Cardiology Guidelines on the management of non-ST-segment elevation ACS 
and ST-segment elevation myocardial infarction positioned bivalirudin as the anticoagulant of choice in 
the PCI setting. Further randomized studies, better reflecting routine clinical practice, revealed significantly 
increased rates of stent thrombosis and myocardial infarction in the bivalirudin arm. Additionally, these 
findings were corroborated in the subsequent meta-analyses. Speculations that excessive occurrence of 
stent thrombosis and myocardial infarction may be caused by too short duration of post PCI bivalirudin 
infusion did not find confirmation in the latest MATRIX trial. In this systematic review, we aim to assess the 
efficacy and safety of bivalirudin therapy in patients undergoing PCI and to formulate recommendations 
on the bivalirudin use for clinicians. In our opinion, the research evidence and pharmacoeconomic con-
siderations strongly support the use of bivalirudin in PCI patients at high risk of bleeding complications, 
while in other situations old and inexpensive UFH or enoxaparin remain the first line antithrombotic drugs.
Key words: bivalirudin, thrombin, antithrombotic treatment, acute coronary syndrome, percutaneous 
coronary intervention
Folia Medica Copernicana 2015; 3 (3): 79–88
Corresponding author: 
Karolina Obońska, MD, PhD 
Department of Cardiology and Internal 
Medicine, Collegium Medicum, 
Nicolaus Copernicus University 
9 Skłodowskiej-Curie Street, 
85–094 Bydgoszcz, Poland 
Tel.: +48 52 585 40 23 
Fax: +48 52 585 40 24 
E-mail: kalaobonska@op.pl
Folia Medica Copernicana 2015; 
Volume 3, Number 3, 79–88  
10.5603/FMC.2015.0001
Copyright © 2015 Via Medica 
ISSN 2300–5432
Introduction
Coronary artery disease (CAD) remains the lead-
ing cause of death worldwide. All over the world over 
seven millions of people die from CAD annually, which 
accounts for 13.1% of all deaths [1]. In Europe, every 
sixth man and every seventh woman is expected to 
die from myocardial infarction (MI) [2]. The mainstay 
of treatment in patients with acute coronary syn-
dromes (ACS) includes intensive antithrombotic and 
anti-ischemic therapy together with invasive coron-
ary procedures. Primary percutaneous coronary 
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intervention (PCI), when compared with thrombolytic 
therapy, was demonstrated to reduce all-cause mor-
tality as well as re-MI and stroke rates in patients with 
ST-segment elevation myocardial infarction (STEMI) 
and therefore, is considered the preferred reperfusion 
strategy in this setting (class of indication I, level of 
evidence A) [2]. Additionally, currently the majority 
of subjects with non-ST-segment elevation ACS also 
undergo PCI procedures. In this setting, interventional 
treatment, when compared with conservative strategy, 
prevents recurrent episodes of coronary ischemia and 
in intermediate- to high-risk patients is associated with 
improved survival and lower risk of MI. PCI procedures 
effectively restore patency of culprit coronary arteries 
and improve myocardial perfusion [3]. Importantly, PCI 
interventions are performed in a highly thrombogenic 
environment. Intracoronary thrombosis triggered by 
ruptured or eroded atherosclerotic plaques constitutes 
the predominant underlying cause of ACS events. 
Exposure of subendothelial proteins to the flowing blood 
at sites of plaque disruption leads to platelets activation 
and aggregation as well as to the release of vasoactive 
and procoagulant mediators. In details, tissue factor (TF) 
originating from the unstable coronary plaques in-
duces thrombin generation, which may result in the 
formation of a platelet- and fibrin-rich intracoronary 
thrombus. Thrombin is considered a central enzyme 
in hemostasis and thrombosis, and a well-established 
target for anticoagulant therapies (Fig. 1) [4]. Anticoagu-
lant regimens utilized during PCI procedures include: 
unfractionated heparin (UFH), low molecular weight hep-
arins, particularly enoxaparin and bivalirudin [2, 5–9]. 
Recently, numerous randomized trials on the role 
of bivalirudin in patients undergoing PCI have been 
published. Their inconsistent results, arising from the 
important differences in study designs and changes in 
interventional practice, have fueled an ongoing debate 
on bivalirudin in the cardiological community. Therefore, 
we aim to conduct a systematic review in order to assess 
the efficacy and safety of bivalirudin therapy in patients 
undergoing PCI and to formulate recommendations on 
the bivalirudin use for clinicians.
Search strategy
A systematic investigation of all published and 
unpublished literature, including oral presentations, 
was conducted to minimize the risk of bias. Briefly, we 
followed the PRISMA statement for reporting systematic 
reviews in health care interventions [10]. A database 
search including PubMed and Google Scholar databas-
es, without time limitations, was conducted on 3rd Sep-
tember 2015 by two independent investigators (K.O. and 
M.K.). Proceedings from the Scientific Sessions of the 
American College of Cardiology (http://www.acc.org), 
American Heart Association (http://www.heart.org), Eu-
ropean Society of Cardiology (http://www.escardio.org) 
were also considered. The following key words were 
applied: “bivalirudin”, “hirulog”, “bivalirudin” and “per-
cutaneous coronary intervention”, and “hirulog” and 
“percutaneous coronary intervention”. References of 
the retrieved studies were searched manually for ad-
ditional studies and reviews. No language restrictions 
were applied. Data were abstracted on prespecified 
forms. All divergences were resolved by discussion with 
a third investigator (JK). Reviews were also considered 
a source of citations of the relevant studies and inter-
pretation of their results.
After a systematic search 24,343 citations were iden-
tified: 2,661 in PubMed, 17,840 in Google Scholar, and 
3,842 in other databases. Duplicate / multiple citations 
and reviews not containing any relevant information 
were excluded. Eventually, 44 original reports and 
Figure 1. Target of bivalirudin in the coagulation cascade; V, VII, VIII, IX, X, XI, XII, XIII — coagulation factors; a — active 
form; Ca2+ — calcium ions; PL — platelet membrane phospholipids; TF — tissue factor
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Figure 2. Chemical structure of bivalirudin (C98H138N24O33)
Figure 3. Interactions between bivalirudin and thrombin. Bivalirudin binds to both active site and exosite 1. Bivalirudin 
inhibits both fibrin-bound and soluble thrombin. Cleaved bivalirudin can be displaced by competitive substrates; A — active 
site (catalytic site responsible for enzymatic actions of thrombin); E1 — exosite 1 (substrate recognition and fibrinogen-
-binding site); E2 — exosite 2 (heparin-binding site)
reviews directly related to the rationale for bivalirudin 
therapy in patients undergoing PCI, pharmacological 
properties of bivalirudin, and clinical studies on bi-
valirudin were considered eligible for inclusion in the 
systematic review.
Pharmacological properties of 
bivalirudin
Bivalirudin, a synthetic analog of the carboxy termi-
nus of hirudin, is a reversible, direct thrombin inhibitor 
(Fig. 2). It exerts a predictable anticoagulant effect, since 
it does not bind to plasma proteins. Notably, bivalirudin 
does not require antithrombin for its anticoagulant ac-
tion and inhibits both fibrin-bound and soluble thrombin 
(Fig. 3). Additionally, bivalirudin binds to both active 
site and exosite 1 of thrombin, thereby competing with 
exosite 1 for fibrin binding and enhancing displace-
ment of thrombin from fibrin. Following its binding to 
bivalirudin, thrombin cleaves the Pro-Arg bond within 
the amino terminal of bivalirudin allowing the recovery 
of thrombin activity. Bivalirudin has a plasma half-life 
of 25 minutes after its intravenous administration and 
only 20% of the given dose is cleared through kidneys 
[3, 11–13]. According to the experiments performed by 
Butenas et al. [14], increasing concentrations of bivaliru-
din prolong the initiation phase of thrombin generation 
in a concentration-dependent manner. Interestingly, 
the investigators demonstrated an increased thrombin 
generation at subpharmacologic concentrations of 
bivalirudin (0.5–2.0 µmol/L), however, at a pharmaco-
logic concentration (5.0 µmol/L) bivalirudin effectively 
suppressed thrombin generation and inhibited platelet 
activation by around 80%. These observations led to the 
conclusion that bivalirudin acts not as a modulator but 
as an ‘on-off’ switch of blood coagulation [14]. Tanaka 
et al. demonstrated substantial differences between 
heparin and bivalirudin in terms of the kinetics of throm-
bus formation [15]. In the blood samples collected from 
12 healthy volunteers, the authors found that increasing 
concentrations of bivalirudin and heparin progressively 
delayed the onset of thrombin formation, but only hepa-
rin dose-dependently decreased the amount of gener-
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ated thrombin. Importantly, Anand et al. demonstrated 
an independent from clopidogrel therapy antiplatelet 
effect of bivalirudin v. UFH during PCI [16]. Moreover, 
this study showed that bivalirudin alone or coupled with 
clopidogrel may confer an anti-inflammatory effect by 
reducing sCD40L during PCI [16]. Anti-inflammatory 
properties of bivalirudin were confirmed in another study 
including 46 patients undergoing elective PCI [17]. 
Platelet surface expression of PAC-1, P-selectin and 
GP Ib alpha were significantly reduced after PCI in bivali-
rudin-treated patients as compared with those receiving 
UFH. Similarly, CD11b expression on CD14+ mono-
cytes was diminished after bivalirudin administration. 
Additionally, the opposite effects of heparin and bivali-
rudin on platelet adhesion were shown in vitro by Eslam 
et al. [18]. In this study, platelet adhesion increased by 
10% with UFH when compared with the baseline values, 
while a corresponding decrease by 20% was observed 
with bivalirudin (p = 0.0047). Furthermore, in a study 
by Pepke et al. [19], bivalirudin, but not UFH, reduced 
post-PCI expression of P-selectin in unstimulated and 
adenosine diphosphate (ADP)-induced platelets. More-
over, bivalirudin inhibited the thrombin, but not VIIa- or 
VIIa/X-induced TF expression and pro-coagulant TF 
activity of smooth muscle cells. The observations de-
rived from the above discussed studies suggest that 
bivalirudin reduces platelet and monocyte activation in 
patients undergoing PCI [15–19] and therefore bivaliru-
din seems to be a potentially better anticoagulant than 
UFH in this setting.
Results of initial randomized clinical 
trials: a rising star…
After initial randomized clinical trials were pub-
lished, this hope became more realistic. In details, the 
ACUITY (Acute Catheterization and Urgent Intervention 
Triage Strategy) investigators randomly assigned 
13,819 moderate or high risk ACS patients undergoing 
invasive management to one of three antithrombotic 
regimens: UFH or enoxaparin plus a glycoprotein 
IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa 
inhibitor, or bivalirudin with bailout use of a glycopro-
tein IIb/IIIa inhibitor [20]. The use of bivalirudin plus 
a glycoprotein IIb/IIIa inhibitor, as compared with UFH 
or enoxaparin plus a glycoprotein IIb/IIIa inhibitor, was 
associated with similar 30-day rates of the composite 
ischemia end point (death, MI, or unplanned coronary 
revascularization for ischemia: 7.7% v. 7.3%; relative 
risk [RR] 1.07; 95% confidence interval [CI] 0.92–1.23; 
p = 0.39), major bleeding (5.3% v. 5.7%; RR 0.93; 95% 
CI 0.78–1.10; p = 0.38), and the net clinical outcome 
end point (composite of the ischemia end point and 
major bleeding: 11.8% v. 11.7%; RR 1.01; 95% CI 
0.90–1.12; p = 0.93). Similarly, when bivalirudin was 
used alone, as compared with UFH or enoxaparin plus 
a glycoprotein IIb/IIIa inhibitor, there was no difference 
in the rate of composite ischemia end point (7.8% v. 
7.3%; RR 1.08; 95% CI 0.93–1.24; p = 0.32), but the 
rates of major bleeding (3.0% v. 5.7%; RR 0.53; 95% 
CI 0.43–0.65; p < 0.001) and net clinical outcome end 
point (10.1% v. 11.7%; RR 0.86; 95% CI 0.77–0.97; 
p = 0.02) were significantly reduced. Additionally, at 
1 year, no statistically significant differences in the rates 
of composite ischemia end point or mortality with the 
3 compared therapies were found [21].
The most favorable results for bivalirudin among 
all so far conducted randomized clinical studies 
were achieved in the HORIZONS-AMI (Harmonizing 
Outcomes with Revascularization and Stents in Acute 
Myocardial Infarction) trial [22]. This study included 
3,602 STEMI patients undergoing primary PCI. The 
investigators demonstrated that anticoagulation 
with bivalirudin alone, as compared with UFH plus 
a glycoprotein IIb/IIIa inhibitor, resulted in a reduced 
30-day rate of net adverse clinical events, defined as 
the combination of major bleeding or major adverse 
cardiovascular events, including death, reinfarction, 
target-vessel revascularization for ischemia and stroke 
(9.2% v. 12.1%; RR 0.76; 95% CI 0.63–0.92; p = 0.005), 
owing to a lower rate of major bleeding (4.9% v. 8.3%; 
RR 0.60; 95% CI 0.46–0.77; p < 0.001). Importantly, 
treatment with bivalirudin alone, as compared with UFH 
plus a glycoprotein IIb/IIIa inhibitor, resulted in signifi-
cantly lower 30-day rates of death from cardiac causes 
(1.8% v. 2.9%; RR 0.62; 95% CI 0.40–0.95; p = 0.03) 
and death from all causes (2.1% v. 3.1%; RR 0.66; 95% 
CI 0.44–1.00; p = 0.047). Unfortunately, there was an 
increased risk of acute stent thrombosis (within 24 h) 
in the bivalirudin group (1.3% v. 0.3%; p < 0.001), but 
no significant increase was present by 30 days (2.5% 
v. 1.9%; p = 0.30). At 3-year follow-up, the superiority 
of bivalirudin monotherapy over the combination of 
UFH and a glycoprotein IIb/IIIa inhibitor became even 
more evident. Compared with 1,802 patients allocated 
to receive UFH plus a glycoprotein IIb/IIIa inhibitor, 
1,800 patients allocated to bivalirudin monotherapy had 
lower rates of all-cause mortality (5.9% v. 7.7%; hazard 
ratio [HR] 0.75; 95% CI 0.58–0.97; p = 0.03), cardiac 
mortality (2.9% v. 5.1%; HR 0.56; 95% CI 0.40–0.80; 
p = 0.001), re-MI (6.2% v. 8.2%; HR 0;76; 95% CI 
0.59–0.99; p = 0.04), and major bleeding not related to 
bypass graft surgery (6.9% v. 10.5%; HR 0.64; 95% CI 
0.51–0.80; p = 0.0001), with no significant differences 
in ischemia-driven target vessel revascularization, stent 
thrombosis, or composite adverse events [23].
Another large study, the EUROMAX (European 
Ambulance Acute Coronary Syndrome Angiography) 
trial, tested in 2,218 STEMI patients whether prehospital 
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administration of bivalirudin continued for 4 hours after 
primary PCI improves clinical outcomes compared with 
the guideline-recommended UFH or enoxaparin [24]. 
The investigators revealed that bivalirudin, as com-
pared with the control intervention, reduced the risk 
of the primary outcome, which was a composite of 
death or major bleeding not associated with coronary 
artery bypass grafting (CABG) at 30 days, (5.1% v. 
8.5%; RR 0.60; 95% CI 0.43–0.82; p = 0.001) and the 
principal secondary outcome, defined as a composite 
of death, re-MI, or non-CABG major bleeding (6.6% v. 
9.2%; RR 0.72; 95% CI 0.54–0.96; p = 0.02). Bivalirudin 
also reduced the risk of major bleeding (2.6% v. 6.0%; 
RR 0.43; 95% CI 0.28–0.66; p < 0.001). Similarly to 
the previously discussed study, the risk of acute stent 
thrombosis was higher with bivalirudin (1.1% v. 0.2%; 
RR 6.11; 95% CI 1.37–27.24; p = 0.007). There was no 
significant difference in rates of death (2.9% v. 3.1%) 
or re-MI (1.7% v. 0.9%) [25].
Based on the results of the above discussed ran-
domized clinical trials, the 2011 and 2012 European 
Society of Cardiology Guidelines on the management of 
non-ST-segment elevation ACS and STEMI positioned 
bivalirudin as the anticoagulant of choice in the PCI 
setting (Tab. 1).
Black clouds over bivalirudin according 
to the recent trials 
A recently published an open-label, single centre, 
randomized HEAT-PPCI (How Effective are Antithrom-
botic Therapies in Primary Percutaneous Coronary 
Intervention) trial comparing bivalirudin v. UFH alone in 
the STEMI setting unexpectedly revealed an excess of 
cardiac ischemic events (the primary efficacy outcome 
— a composite of all-cause mortality, cerebrovascular 
accident, re-MI, or unplanned target lesion revascu-
larization: 8.7% v. 5.7%; RR 1.52; 95% CI 1.09–2.13; 
p = 0.01) associated with bivalirudin therapy, which was 
predominantly driven by the significantly increased rate 
of MI in the bivalirudin group (2.7% v. 0.9%; RR 3.01; 
95% CI 1.36–6.66; p = 0.004), and no difference in 
major bleeding events between both study arms (type 
3–5 bleedings according to the Bleeding Academic 
Research Consortium classification: 3.5% v. 3.1%; 
RR 1.15; 95% CI 0.70–1.89; p = 0.59) [26].
These data suggest that the inconsistency between 
the results of the HEAT-PPCI trial and the previously con-
ducted studies may be driven by the concomitant ad-
ministration of a glycoprotein IIb/IIIa inhibitor in heparin- 
-treated patients. A recently published meta-analysis 
of 13 randomized studies including 24,605 patients 
showed that the incidence of 30-day all-cause death 
as well as 30-day MI did not differ significantly between 
the bivalirudin and UFH groups, independently of the 
concomitant use of a glycoprotein IIb/IIIa inhibitor 
[20, 22, 26–39]. The rate of 30-day major bleeding 
events was significantly lower in bivalirudin-treated 
patients as compared with those receiving UFH with 
the routine use of a glycoprotein IIb/IIIa inhibitor (odds 
ratio [OR] 0.52; 95% CI 0.45–0.60; p < 0.001), but not 
if compared with the UFH plus provisional adminis-
tration of a glycoprotein IIb/IIIa inhibitor group (OR 
0.66, 95% CI 0.33–1.32; p = 0.24). The overall rate of 
30-day definite stent thrombosis increased significantly 
with bivalirudin as compared with coadministration of 
UFH and a glycoprotein IIb/IIIa inhibitor (OR 1.67; 95% CI 
1.13–2.45; p = 0.01). The prevalence of stent throm-
bosis was also numerically greater with bivalirudin as 
compared with heparin plus provisionally administered 
glycoprotein IIb/IIIa inhibitor. However, the difference 
did not reach statistical significance (OR 2.08; 95% CI 
0.35–12.32; p = 0.42). Bivalirudin treatment was 
associated with a significant increase in the odds of 
acute stent thrombosis (≤ 24h), but not of subacute 
stent thrombosis (> 24h-30 days), when compared 
with heparin administration (acute stent thrombosis: 
OR 4.49; 95% CI 2.42–8.36; p < 0.001; subacute stent 
thrombosis: OR 1.10; 95% CI 0.62–1.97; p = 0.74). The 
magnitude and direction of the estimates were consis-
tent independently from the use of a glycoprotein IIb/IIIa 
inhibitor in UFH-treated patients. The overall effect of 
the treatment, however, is reflected by the net adverse 
clinical events (NACE) rate, defined as a composite of 
ischemic events (death, MI, repeat revascularization, 
along with ST and stroke) and major bleeding. There 
were significantly fewer NACE with bivalirudin com-
pared with UFH plus the routine use of a glycoprotein 
IIb/IIIa inhibitor (OR 0.77; 95% CI 0.65–0.91; p = 0.002). 
A numerical reduction in the odds of NACE in bivaliru-
din-treated patients was not-significant as compared 
with UFH without the routine use of a glycoprotein IIb/IIIa 
inhibitor (OR 0.76; 95% CI 0.51–1.13; p = 0.18) [39]. 
Another recent meta-analysis by Kianoush et al. in-
cluding 41,243 patients from 25 randomized trials, 
demonstrated that the use of bivalirudin compared with 
active control was associated with an increased risk of 
definite stent thrombosis (RR 1.73; 95% CI 1.24–2.40; 
p < 0.001; number needed to harm [NNH] 182), sim-
ilar risk of MI (RR 1.00; 95% CI 0.87–1.16; p = 0.96), 
decreased risk of major bleeding (RR 0.59; 95% CI 
0.49–0.72; p < 0.001; number needed to treat [NNT] 79) 
and of cardiac death (RR 0.72; 95% CI 0.53–0.99; 
p = 0.05), but no effect on all-cause mortality (RR 0.96; 
95% CI 0.81–1.15; p = 0.69) [40].
All available research evidence consistently shows 
that therapy with bivalirudin in ACS patients is asso-
ciated with a significant reduction of major bleeding 
when compared with the regimen including UFH and 
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Table 1. Recommendations of the European Society of Cardiology on the anticoagulation in patients undergoing PCI, 
with a particular emphasis on the use of bivalirudin
CAD  
setting
Recommendation Class of  
recommendation
Level of 
evidence
2011 ESC Guidelines on NSTE-ACS [5]
NSTE-ACS Bivalirudin plus provisional GP IIb/IIIa receptor inhibitors are recommended  
as an alternative to UFH plus GP IIb/IIIa receptor inhibitors in patients with  
an intended urgent or early invasive strategy, particularly in patients  
with high risk of bleeding
I B
2012 ESC Guidelines on STEMI [2]
STEMI Bivalirudin (with use of GP IIb/IIIa blocker restricted to bailout)  
is recommended over UFH and a GP IIb/IIIa blocker
I B
Enoxaparin (with or without routine GP IIb/IIIa blocker) may be preferred  
over unfractionated heparin
IIb B
Unfractionated heparin with or without routine GP IIb/IIIa blocker must  
be used in patients not receiving bivalirudin, or enoxaparin
I C
Fondaparinux is not recommended for primary PCI III B
2014 ESC Guidelines on myocardial revascularization [6]
SCAD UFH 70–100 U/kg I B
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h for up to 4 h  
after the procedure) in case of heparin-induced thrombocytopenia
I C
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h during  
the procedure) in patients at high bleeding risk
IIa A
Enoxaparin i.v. 0.5 mg/kg IIa B
STEMI The anticoagulation is selected according to both ischemic and bleeding  
risks, and according to the efficacy–safety profile of the chosen agent
I C
Unfractionated heparin: 70–100 U/kg i.v. bolus when no GP IIb/IIIa inhibitor  
is planned; 50–70 U/kg i.v. bolus with GP IIb/IIIa inhibitor
I C
Bivalirudin 0.75 mg/kg i.v. bolus, followed by i.v. infusion of 1.75 mg/kg/h  
for up to 4 h after the procedure
IIa A
Enoxaparin i.v. 0.5 mg/kg with or without GP IIb/IIIa inhibitor IIa B
NSTE-ACS The anticoagulation is selected according to both ischemic and bleeding  
risks, and according to the efficacy–safety profile of the chosen agent
I C
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h for up to 4 h  
after the procedure) is recommended as alternative to UFH plus GP IIb/IIIa 
receptor inhibitor during PCI
I A
UFH is recommended as anticoagulant for PCI if patients cannot receive 
bivalirudin
I C
Enoxaparin should be considered as anticoagulant for PCI in patients pre-
treated with subcutaneous enoxaparin
IIa B
2015 ESC Guidelines on NSTE-ACS [7]
NSTE-ACS Bivalirudin (0.75 mg/kg i.v. bolus, followed by 1.75 mg/kg/h for up to 4 h  
after the procedure) is recommended as an alternative to UFH  
plus GP IIb/IIIa inhibitors during PCI
I A
NSTE-ACS UFH 70–100 IU/kg i.v. (50–70 IU/kg if concomitant with GPIIb/IIIa inhibitors) 
is recommended in patients undergoing PCI who did not receive any 
anticoagulant
I B
NSTE-ACS Enoxaparin should be considered as an anticoagulant for PCI in patients 
pretreated with s.c. enoxaparin
IIa B
CAD — coronary artery disease; ECS — European Society of Cardiology; GP — glycoprotein; NSTE-ACS — non-ST-segment elevation acute 
coronary syndrome; PCI — percutaneous coronary intervention; SCAD — stable coronary artery disease; STEMI — ST-segment elevation  
myocardial infarction; UFH — unfractionated heparin
85
Karolina Obońska et al., Bivalirudin in patients undergoing PCI
www.fmc.viamedica.pl
a glycoprotein IIb/IIIa inhibitor. Bivalirudin also poses 
an increased risk of acute stent thrombosis when 
compared with heparin routinely or provisionally 
coadministered with a glycoprotein IIb/IIIa inhibitor. 
These facts together with a short half-life of bivalirudin 
(around 25 min) led to the formulation of the hypothe-
sis that excessive rates of stent thrombosis and MI ob-
served in bivalirudin-treated patients may be related 
to the short duration of bivalirudin infusion and/or the 
timing and potency of the administered antiplatelet 
agents [41]. This hypothesis was initially supported by 
a study published by Cortese et al. [42]. The authors 
compared the effects of bivalirudin given as a bolus 
followed by 4-hour infusion v. bivalirudin given as 
a bolus followed by peri-PCI infusion v. a bolus of UFH 
on top of abciximab. The study population consisted 
of 264 STEMI patients undergoing primary PCI who 
were pretreated with aspirin and clopidogrel. The pri-
mary study end point, defined as > 70% ST-segment 
resolution within 90 minutes after PCI, was achieved 
in 69.8%, 48.8%, and 69.6% of patients, respectively 
(p = 0.048 for the comparison between the prolonged 
and standard bivalirudin infusion groups, p = 0.98 for 
the comparison between the prolonged bivalirudin 
infusion and UFH plus abciximab groups). Major 
bleedings were not significantly different among the 
study arms. The encouraging results suggested that 
the strategy of prolonged bivalirudin infusion after 
primary PCI, but not peri-PCI bivalirudin infusion, may 
be equivalent to the strategy with UFH plus abciximab 
in the STEMI setting [42]. 
However, this enthusiasm was tempered by the 
recently published findings of the MATRIX (Minimizing 
Adverse Haemorrhagic Events by TRansradial Access 
Site and Systemic Implementation of angioX) trial [43]. 
The investigators randomly assigned 7,213 ACS pa-
tients for whom PCI was anticipated to receive either 
bivalirudin or UFH. Patients in the bivalirudin group 
were subsequently randomly assigned to receive or 
not to receive a post-PCI bivalirudin infusion. Primary 
outcomes for the comparison between bivalirudin 
and heparin were the occurrence of major adverse 
cardiovascular events (a composite of death, myo-
cardial infarction, or stroke) and net adverse clinical 
events (a composite of major bleeding or a major 
adverse cardiovascular event). Clinical follow-up was 
performed at 30 days. The primary outcome for the 
comparison of a post-PCI bivalirudin infusion with no 
post-PCI infusion was a composite of urgent target- 
-vessel revascularization, definite stent thrombosis, 
or net adverse clinical events. Bivalirudin failed to 
reduce the rates of both major adverse cardiovascular 
events (10.3% v. 10.9%; RR 0.94; 95% CI 0.81–1.09; 
p = 0.44) and net adverse clinical events (11.2% 
v. 12.4%; RR 0.89; 95% CI 0.78–1.03; p = 0.12) as 
compared with UFH. Moreover, post-PCI bivalirudin 
infusion, as compared with no infusion, did not sig-
nificantly decrease the rate of urgent target-vessel 
revascularization, definite stent thrombosis, or net 
adverse clinical events (11.0% v. 11.9%; RR 0.91; 95% 
CI 0.74–1.11; p = 0.34). In this study, there was no 
significant difference in the rate of definite or probable 
stent thrombosis between the groups (1.3% v. 1.0%; 
RR 1.28; 95% CI 0.82–2.00; p = 0.27), although the 
rate of definite stent thrombosis was higher in the 
bivalirudin group (1.0% v. 0.6%; RR 1.71; 95% CI 
1.00–2.93; p = 0.048). Contrary to the expectations, 
post-PCI infusion of bivalirudin, as compared with no 
post-PCI infusion, did not lower the rate of definite 
stent thrombosis (1.3% v. 0.7%; RR 1.78; 95% CI 
0.90–3.53; p = 0.09) [43]. Consistently with some 
of the previous reports [22, 25], the MATRIX inves-
tigators found a lower rate of major bleeding (1.7% 
v. 2.3%; RR 0.71; 95% CI 0.51–0.99; p = 0.04) and 
lower all-cause mortality (1.4% v. 2.5%; RR 0.55; 95% 
CI 0.39–0.78; p < 0.001) in bivalirudin v. UFH-treated 
patients [43]. Interestingly, the authors raised the 
issue of the differences in definitions of individual 
elements of composite outcomes in other studies 
which might have influenced the interpretation of 
their results. However, the definition of re-MI used 
in the MATRIX study was in agreement with the third 
universal definition of myocardial infarction.
In general, the results of the recently published 
randomized studies are much less favorable for 
bivalirudin than the initial ones (Tab. 2) [20–45]. 
This fact is reflected in the latest guidelines of the 
European Society of Cardiology where the role of 
bivalirudin in patients undergoing PCI was consider-
ably downgraded (Tab. 1). The discrepancy in the 
trial results may be multicausal. First of all, some of 
the landmark studies (e.g. the HORIZONS-AMI trial) 
were suboptimally designed, favoring bivalirudin. The 
bleeding benefit identified in the older studies seems 
to be caused rather by a higher bleeding incidence 
in the comparator arm due to the disproportional 
use of a glycoprotein IIb/IIIa inhibitor with heparin 
than beneficial properties of bivalirudin. Additionally, 
recent changes in interventional practice, such as 
increasing use of radial access, lower doses of UFH, 
decreased use of glycoprotein IIb/IIIa inhibitors and 
administration of more effective platelet P2Y12 recep-
tor inhibitors, are suggested to diminish the benefits 
of bivalirudin v. UFH therapy. Although bivalirudin 
is currently reimbursed in the majority of European 
countries, including Poland, pharmacoeconomic 
considerations clearly favor UFH or enoxaparin over 
bivalirudin in the PCI setting.
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Conclusions
In our opinion, the research evidence and pharmaco-
economic considerations presented above strongly 
support the use of bivalirudin in PCI patients at high 
risk of bleeding complications, while in other situations 
old and inexpensive UFH or enoxaparin remain the first 
line antithrombotic drugs.
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